OBJECTIVE: The aim of this study was to evaluate the influence of sex on response to treatment and disease remission in patients with axial spondyloarthritis (axSpA). METHODS: In this retrospective multicenter study, patients with axSpA, according to the Assessment of Spondyloarthritis international Society (ASAS) criteria for axSpA, and treated with adalimumab, etanercept, golimumab, or infliximab, were studied. We compared clinical characteristics, patient-reported outcomes, disease activity, function, and response to treatment in male and female patients with this disease. RESULTS: Three hundred forty patients with axSpA (270 with ankylosing spondylitis, 19 with psoriatic arthritis with axial involvement, and 51 with nonradiographic axSpA) were studied. Male subjects had a significantly higher prevalence of grade IV sacroiliitis, higher levels of serum C-reactive protein, lower Maastricht Ankylosing Spondylitis Enthesitis Score, and fatigue when compared with females. Further, Kaplan-Meier survival curves showed that the rate of partial remission, ASAS40 response, and Ankylosing Spondylitis Disease Activity Score (ASDAS) major improvement, but not ASDAS inactive disease, were significantly lower in female patients. CONCLUSION: Our data suggest that female sex was associated with a lower rate of response to treatment and of disease remission in patients with axSpA treated with antitumor necrosis factor-α drugs.

The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis / Lubrano, Ennio; Perrotta, Fabio Massimo; Manara, Maria; D'Angelo, Salvatore; Addimanda, Olga; Ramonda, Roberta; Punzi, Leonardo; Olivieri, Ignazio; Salvarani, Carlo; Marchesoni, Antonio. - In: THE JOURNAL OF RHEUMATOLOGY. - ISSN 0315-162X. - 45:2(2018), pp. 195-201. [10.3899/jrheum.17666]

The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis

Salvarani, Carlo;
2018

Abstract

OBJECTIVE: The aim of this study was to evaluate the influence of sex on response to treatment and disease remission in patients with axial spondyloarthritis (axSpA). METHODS: In this retrospective multicenter study, patients with axSpA, according to the Assessment of Spondyloarthritis international Society (ASAS) criteria for axSpA, and treated with adalimumab, etanercept, golimumab, or infliximab, were studied. We compared clinical characteristics, patient-reported outcomes, disease activity, function, and response to treatment in male and female patients with this disease. RESULTS: Three hundred forty patients with axSpA (270 with ankylosing spondylitis, 19 with psoriatic arthritis with axial involvement, and 51 with nonradiographic axSpA) were studied. Male subjects had a significantly higher prevalence of grade IV sacroiliitis, higher levels of serum C-reactive protein, lower Maastricht Ankylosing Spondylitis Enthesitis Score, and fatigue when compared with females. Further, Kaplan-Meier survival curves showed that the rate of partial remission, ASAS40 response, and Ankylosing Spondylitis Disease Activity Score (ASDAS) major improvement, but not ASDAS inactive disease, were significantly lower in female patients. CONCLUSION: Our data suggest that female sex was associated with a lower rate of response to treatment and of disease remission in patients with axSpA treated with antitumor necrosis factor-α drugs.
2018
45
2
195
201
The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis / Lubrano, Ennio; Perrotta, Fabio Massimo; Manara, Maria; D'Angelo, Salvatore; Addimanda, Olga; Ramonda, Roberta; Punzi, Leonardo; Olivieri, Ignazio; Salvarani, Carlo; Marchesoni, Antonio. - In: THE JOURNAL OF RHEUMATOLOGY. - ISSN 0315-162X. - 45:2(2018), pp. 195-201. [10.3899/jrheum.17666]
Lubrano, Ennio; Perrotta, Fabio Massimo; Manara, Maria; D'Angelo, Salvatore; Addimanda, Olga; Ramonda, Roberta; Punzi, Leonardo; Olivieri, Ignazio; Salvarani, Carlo; Marchesoni, Antonio
File in questo prodotto:
File Dimensione Formato  
195.full.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 680.41 kB
Formato Adobe PDF
680.41 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1155242
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 62
  • ???jsp.display-item.citation.isi??? 43
social impact